2-Benzyl-N-[1-(1-cyclohexylmethyl-2,3-dihydroxy-5-methyl-hexylcarbamoyl)-2-thiazol-4-yl-ethyl]-3-(4-methyl-piperazine-1-sulfonyl)-propionamide (Zankiren (A-72517))

ID: ALA113841

Chembl Id: CHEMBL113841

Cas Number: 138742-43-5

PubChem CID: 3086652

Max Phase: Unknown

Molecular Formula: C35H55N5O6S2

Molecular Weight: 705.99

Molecule Type: Small molecule

Names and Identifiers

Synonyms: A-72517 | Zankiren|138742-43-5|Zankiren [INN]|A 72517|CHEMBL113841|I36B16A34Q|A-72517|(2S)-2-benzyl-N-[(2S)-1-[[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]amino]-1-oxo-3-(1,3-thiazol-4-yl)propan-2-yl]-3-(4-methylpiperazin-1-yl)sulfonylpropanamide|4-Thiazolepropanamide, N-((1S,2R,3S)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2S)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphaS)-|UNII-I36B16A34Q|ZANKIREN [WHO-DD]|SCHEMBL180700|DTXSIShow More⌵

Synonyms from Alternative Forms(3): Zankiren hcl | Zankiren hydrochloride | ABBOTT-72517

Canonical SMILES:  CC(C)C[C@H](O)[C@H](O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cscn1)NC(=O)[C@H](Cc1ccccc1)CS(=O)(=O)N1CCN(C)CC1

Standard InChI:  InChI=1S/C35H55N5O6S2/c1-25(2)18-32(41)33(42)30(20-27-12-8-5-9-13-27)37-35(44)31(21-29-22-47-24-36-29)38-34(43)28(19-26-10-6-4-7-11-26)23-48(45,46)40-16-14-39(3)15-17-40/h4,6-7,10-11,22,24-25,27-28,30-33,41-42H,5,8-9,12-21,23H2,1-3H3,(H,37,44)(H,38,43)/t28-,30+,31+,32+,33-/m1/s1

Standard InChI Key:  YFDSDRDMDDGDFC-HOQQKOLYSA-N

Alternative Forms

1. Parent:

   

   ALA113841

   ZANKIREN

2. Alternative Forms:

   

   ALA113841

   ZANKIREN HYDROCHLORIDE

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: Yes

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 705.99

Molecular Weight (Monoisotopic): 705.3594

AlogP: 2.83

#Rotatable Bonds: 17

Polar Surface Area: 152.17

Molecular Species: NEUTRAL

HBA: 9

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.36

CX Basic pKa: 6.24

CX LogP: 2.86

CX LogD: 2.83

Aromatic Rings: 2

Heavy Atoms: 48

QED Weighted: 0.20

Np Likeness Score: -0.38

References

1. Leung D, Abbenante G, Fairlie DP..  (2000)  Protease inhibitors: current status and future prospects.,  43  (3): [PMID:10669559] [10.1021/jm990412m]

2. Rosenberg SH, Spina KP, Condon SL, Polakowski J, Yao Z, Kovar P, Stein HH, Cohen J, Barlow JL, Klinghofer V..  (1993)  Studies directed toward the design of orally active renin inhibitors. 2. Development of the efficacious, bioavailable renin inhibitor (2S)-2-benzyl-3- [[(1-methylpiperazin-4-yl)sulfonyl]propionyl]-3-thiazol-4-yl-L-alanine amide of (2S,3R,4S)-2-amino-1-cyclohexyl-3,4-dihydroxy-6-methylheptane (A-72517).,  36  (4): [PMID:8474102] [10.1021/jm00056a006]

3. Bezençon O, Bur D, Weller T, Richard-Bildstein S, Remen L, Sifferlen T, Corminboeuf O, Grisostomi C, Boss C, Prade L, Delahaye S, Treiber A, Strickner P, Binkert C, Hess P, Steiner B, Fischli W..  (2009)  Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.,  52  (12): [PMID:19358611] [10.1021/jm900022f]

Source

Source(1):

• Scientific Literature